Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Regeneron Pharmaceuticals, Inc. (REGN) EBITDA
Regeneron Pharmaceuticals, Inc.'s EBITDA for fiscal 2025 was $4.1B, down 7.87% from $4.5B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.4B. Over the past ten years it has ranged from $1.3B (fiscal 2015) to $9.2B (fiscal 2021); the current reading is higher than 64% of that period. Regeneron Pharmaceuticals, Inc. ranks 2nd of 602 Biotechnology companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $4.1B | (7.87%) |
| FY2024 | $4.5B | 0.12% |
| FY2023 | $4.5B | (12.05%) |
| FY2022 | $5.1B | (44.98%) |
| FY2021 | $9.2B | 142.18% |
| FY2020 | $3.8B | 57.53% |
| FY2019 | $2.4B | (9.79%) |
| FY2018 | $2.7B | 20.56% |
| FY2017 | $2.2B | 55.02% |
| FY2016 | $1.4B | 8.18% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $1.4B | 84.99% |
| Mar 2026 | $766.1M | (25.25%) |
| Dec 2025 | $1.0B | (11.91%) |
| Sep 2025 | $1.2B | (4.21%) |
| 42 more quarters | Free account |
Against its own ten years
Low $1.3B
High $9.2B
Ten-year median
$3.8B
Current reading's percentile
64
EBITDA against peers
| Company | EBITDA |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated compare | $5.0B |
| REGN Regeneron Pharmaceuticals, Inc. | $4.4B |
| ARGX argenex SE compare | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.5B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.1B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.1B |
| INSM Insmed, Inc. compare | −$812.5M |
| RVMD Revolution Medicines, Inc. compare | −$1.6B |
| MRNA Moderna, Inc. compare | −$3.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on REGN
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement